Peptide-conjugated PMOs for the treatment of myotonic dystrophy
Antisense oligonucleotides (ASOs) have shown great therapeutic potential in the treatment of many neuromuscular diseases including myotonic dystrophy 1 (DM1). However, systemically delivered ASOs display poor biodistribution and display limited penetration into skeletal muscle. The conjugation of ce...
| المؤلفون الرئيسيون: | , , , , , |
|---|---|
| مؤلفون آخرون: | |
| التنسيق: | Journal article |
| اللغة: | English |
| منشور في: |
Springer
2022
|